Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
Recommended Citation
McClintock TR, von Landenberg N, Cole AP, Lipsitz SR, Gild P, Sun M, Fletcher SA, Roghmann F, Menon M, Nguyen PL, Noldus J, Choueiri TK, Kibel AS, and Trinh QD. Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: Recent trends in utilization and association with postoperative surgical margin status. Ann Surg Oncol 2018; 26(1):297-305.
Document Type
Article
Publication Date
1-1-2019
Publication Title
Annals of surgical oncology : the official journal of the Society of Surgical Oncology
Abstract
PURPOSE: In this study, we sought to describe the contemporary trends in utilization of neoadjuvant androgen deprivation therapy (ADT). As a secondary endpoint, we assessed the community-level effect of neoadjuvant ADT on positive surgical margins after radical prostatectomy (RP).
METHODS: Using the National Cancer Database (2004-2014), we identified patients with clinically localized prostate cancer (PCa) [cT1-4N0M0] treated with RP. The estimated annual percentage change (EAPC) mixed linear regression methodology was used for temporal trend analysis of neoadjuvant ADT. Observed differences in baseline characteristics between patients treated with neoadjuvant ADT versus those who were not were then controlled for using an inverse probability of treatment weighting (IPTW) approach. IPTW-adjusted analyses were then performed to examine the odds of positive surgical margins.
RESULTS: Overall, 8184 (2.12%) and 377,843 (97.88%) individuals with PCa were treated with neoadjuvant ADT prior to RP versus RP only, respectively. There was a consistent trend in decreasing use of neoadjuvant ADT over time, with a nadir observed in 2011 [EAPC - 8.08; 95% confidence interval (CI) - 11.7 to - 4.32; p < 0.05]. In IPTW-adjusted analyses, the odds of positive surgical margins were lower in patients receiving neoadjuvant ADT with low-risk [odds ratio (OR) 0.65; 95% CI 0.51-0.84; p < 0.001] and intermediate-risk [OR 0.76; 95% CI 0.69-0.85; p < 0.001] PCa.
CONCLUSIONS: After a period of steady decline, there appears to be a modest trend towards increased utilization of neoadjuvant ADT in more recent years. We found an association between neoadjuvant ADT and decreased odds of positive surgical margins among low- and intermediate-risk patients.
Medical Subject Headings
Aged; Androgen Antagonists; Follow-Up Studies; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Postoperative Period; Prognosis; Prostatectomy; Prostatic Neoplasms; Survival Rate
PubMed ID
30430324
Volume
26
Issue
1
First Page
297
Last Page
305
